Home » Stocks » PMVP

PMV Pharmaceuticals, Inc. (PMVP)

Stock Price: $35.00 USD -0.12 (-0.34%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.57B
Revenue (ttm) n/a
Net Income (ttm) -34.44M
Shares Out 44.93M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $35.00
Previous Close $35.12
Change ($) -0.12
Change (%) -0.34%
Day's Open 35.47
Day's Range 34.30 - 35.64
Day's Volume 112,358
52-Week Range 29.45 - 63.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CRANBURY, N.J., April 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...

3 weeks ago - GlobeNewsWire

CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...

1 month ago - GlobeNewsWire

CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...

1 month ago - GlobeNewsWire

CRANBURY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...

2 months ago - GlobeNewsWire

CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...

2 months ago - GlobeNewsWire

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...

Other stocks mentioned: AKUS, TARA
3 months ago - GuruFocus

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...

5 months ago - GlobeNewsWire

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...

5 months ago - GlobeNewsWire

CRANBURY, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...

5 months ago - GlobeNewsWire

Andreas Halvorsen (Trades, Portfolio) revealed he established a new position in PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Sept. 25, according to GuruFocus' Real-Time Picks.

7 months ago - GuruFocus

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targetin...

7 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

Other stocks mentioned: AMST, BSY, CRSR, FCACU, GDRX, GLSI, GRAY ...
7 months ago - Seeking Alpha

PMV Pharmaceuticals Inc.'s stock debuted with a bang Friday, as the the stock opened at nearly double the initial public offering price. The first trade was at $35.00 at 12:09 p.m.

7 months ago - Market Watch

PMV Pharmaceuticals Inc.'s PMVP, initial public offering priced at $18 a share, which was at the top of the expected range of $16 to $18 a share. The oncology company said la...

7 months ago - Market Watch

CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targetin...

7 months ago - GlobeNewsWire

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was i... [Read more...]

Industry
Biotechnology
IPO Date
Sep 25, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PMVP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PMVP stock is "Buy." The 12-month stock price forecast is 59.50, which is an increase of 70.00% from the latest price.

Price Target
$59.50
(70.00% upside)
Analyst Consensus: Buy